Cardiac myosin-binding protein C is a novel marker of myocardial injury and fibrosis in aortic stenosis by Anand, Atul et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cardiac myosin-binding protein C is a novel marker of
myocardial injury and fibrosis in aortic stenosis
Citation for published version:
Anand, A, Chin, C, Shah, ASV, Kwiecinski, J, Vesey, A, Cowell, J, Weber, E, Kaier, T, Newby, DE, Dweck,
M, Marber, MS & Mills, NL 2017, 'Cardiac myosin-binding protein C is a novel marker of myocardial injury
and fibrosis in aortic stenosis', Heart. https://doi.org/10.1136/heartjnl-2017-312257
Digital Object Identifier (DOI):
10.1136/heartjnl-2017-312257
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Heart
Publisher Rights Statement:
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC
BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
  1Anand A, et al. Heart 2017;0:1–8. doi:10.1136/heartjnl-2017-312257
ABSTRACT 
Objective Cardiac myosin-binding protein C (cMyC) is 
an abundant sarcomeric protein and novel highly specific 
marker of myocardial injury. Myocyte death characterises 
the transition from hypertrophy to replacement 
myocardial fibrosis in advanced aortic stenosis. We 
hypothesised that serum cMyC concentrations would 
be associated with cardiac structure and outcomes in 
patients with aortic stenosis.
Methods cMyC was measured in two cohorts in which 
serum had previously been prospectively collected: 
a mechanism cohort of patients with aortic stenosis 
(n=161) and healthy controls (n=46) who underwent 
cardiac MRI, and an outcome cohort with aortic stenosis 
(n=104) followed for a median of 11.3 years. 
Results In the mechanism cohort, cMyC concentration 
correlated with left ventricular mass (adjusted β=11.0 
g/m2 per log unit increase in cMyC, P<0.001), fibrosis 
volume (adjusted β=8.0 g, P<0.001) and extracellular 
volume (adjusted β=1.3%, P=0.01) in patients with 
aortic stenosis but not in controls. In those with late 
gadolinium enhancement (LGE) indicative of myocardial 
fibrosis, cMyC concentrations were higher (32 (21–56) 
ng/L vs 17 (12–24) ng/L without LGE, P<0.001). cMyC 
was unrelated to coronary calcium scores. Unadjusted 
Cox proportional hazards analysis in the outcome cohort 
showed greater all-cause mortality (HR 1.49 per unit 
increase in log cMyC, 95% CI 1.11 to 2.01, P=0.009).
Conclusions Serum cMyC concentration is associated 
with myocardial hypertrophy, fibrosis and an increased 
risk of mortality in aortic stenosis. The quantification 
of serum sarcomeric protein concentrations provides 
objective measures of disease severity and their clinical 
utility to monitor the progression of aortic stenosis merits 
further study.
Clinical trial registration NCT1755936;Post-results.
InTROduCTIOn
Aortic stenosis is the most common valvular 
disease in the Western world and the incidence is 
rising in keeping with an ageing population.1 The 
response of the myocardium to aortic stenosis is 
variable, with heterogeneity in the development of 
ventricular hypertrophy and in how this process 
ultimately decompensates.2–4 This results in a 
poor correlation between the severity of stenosis 
and the development of symptoms. Decompen-
sation of the hypertrophic response in aortic 
stenosis is driven by two processes: progressive 
myocyte cell death and myocardial fibrosis.5 
Biomarkers of myocardial injury are therefore an 
attractive addition to current imaging markers 
of disease progression, perhaps providing critical 
evidence of early decompensation that may iden-
tify patients who would benefit from early valve 
replacement. We have previously demonstrated 
that cardiac troponin I concentration is associated 
with advanced hypertrophy, replacement fibrosis 
and poor long-term outcomes in patients with 
aortic stenosis,6 suggesting that myocardial injury 
in advanced aortic stenosis is common, detectable 
and of prognostic importance.
Cardiac myosin-binding protein C (cMyC) is 
a cardiac-restricted sarcomeric protein located 
on the thick filament.7 8 Recent advances in assay 
technology have allowed measurement of cMyC 
with high precision at extremely low concentra-
tions.9 It is more abundant in myocardial tissue 
and the circulation than cardiac troponins and has 
an important role in the assembly and function of 
the cardiac sarcomere.10–12 Indeed, mutations in 
the MYBPC3 gene-encoding cMyC are the most 
common known genetic cause of hypertrophic 
cardiomyopathy.13 Furthermore, the proteolytic 
cleavage of cMyC is highly regulated by a variety 
of myocardial kinases14 and the resultant peptide 
is cardiotoxic.15 Hence, there is growing interest 
in the protein as both a biomarker and a determi-
nant of myocardial injury.16 Given myocyte death 
characterises the transition from hypertrophy to 
replacement myocardial fibrosis in advanced aortic 
stenosis, we hypothesised that serum cMyC concen-
trations would be associated with cardiac structure 
and outcomes in patients with aortic stenosis.
MeThOdS
We evaluated cMyC in two cohorts: a mechanism 
cohort of patients with aortic stenosis and healthy 
controls with cardiac MRI (CMR), and an outcome 
cohort of patients with aortic stenosis with more 
than 10 years of clinical follow-up. These groups 
were derived from existing studies in patients 
with stable aortic stenosis recruited from cardi-
ology clinics across the South East of Scotland, 
where serum had been prospectively collected and 
frozen at the time of study inclusion. Additionally, 
a subgroup of patients from the mechanism cohort 
underwent myocardial biopsy at the time of subse-
quent aortic valve replacement (AVR), providing 
exploratory histological correlation with cMyC 
concentrations. The studies were conducted in 
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accordance with the Declaration of Helsinki. Written informed 
consent was obtained from all participants.
Mechanism cohort
The mechanism cohort consisted of 161 patients with mild to 
severe aortic stenosis and 46 healthy volunteers without evidence 
of significant valvular heart disease enrolled in an observational 
study assessing the role of myocardial fibrosis in aortic stenosis 
(NCT:01755936 post-results). Exclusion criteria comprised 
significant (moderate or severe) non-aortic valvular disease 
or any cardiomyopathy (acquired or inherited). The imaging 
protocol undertaken in all participants has been described in 
detail previously.6 17–19 Briefly, CMR was performed using a 3T 
scanner (MAGNETOM Verio, Siemens AG, Healthcare Sector, 
Erlangen, Germany). Dedicated software was used to assess left 
ventricular (LV) volume and mass indexed to body surface area 
and to calculate ejection fraction. Diffuse myocardial fibrosis 
was determined by fibrosis volume and the extracellular volume 
(ECV) fraction in keeping with current evidence of reproduc-
ibility from T1 mapping.19 20 Focal myocardial replacement 
fibrosis was determined by the late gadolinium enhancement 
(LGE) technique, with its presence determined visually and inde-
pendently by two experienced assessors. Comprehensive echo-
cardiography was performed on all subjects to classify markers 
of aortic stenosis severity according to European Association 
of Echocardiography/American Society of Echocardiography 
guidelines.21
Outcome cohort
This cohort was derived from the Scottish Aortic Stenosis and 
Lipid Lowering Trial, Impact of Regression (SALTIRE) study. 
The study design, recruitment and findings have been reported 
previously.22 23 Briefly, between March 2001 and April 2002, 
a total of 155 patients with asymptomatic moderate to severe 
aortic stenosis were randomised to receive either atorvastatin 
or placebo. Stored sample remained for cMyC analysis in 104 
patients. In addition to comprehensive echocardiography, CT 
calcium scoring of the coronary arteries was performed (Twin II 
Flash, Philips Medical Systems).
Outcomes data were obtained by two independent investiga-
tors who were blinded to cMyC results. The General Register 
of Scotland was searched for all deaths. The cause of death 
was adjudicated for a cardiac cause using additional informa-
tion from electronic health records if necessary. Disagreements 
were resolved by consensus. Electronic health records were also 
reviewed in all cases for evidence of surgical AVR.
Blood sampling and analysis
Serum cMyC concentrations were measured in duplicate on 
the single molecule counting Erenna platform (Singulex/Merck 
Millipore, CA, USA). The assay has a lower limit of detec-
tion (LoD) of 0.4 ng/L, a lower limit of quantification (LLoQ) 
of 1.2 ng/L (at 20% coefficient of variation, CV) and reason-
able recovery (107.1%±3.7%; mean±SD), dilutional linearity 
(101.0%±7.7%), and intraseries (CV 11%±3%) and interseries 
(CV 13%±3%) precision. Cardiac troponin was determined 
using a high-sensitivity assay (Abbott ARCHITECT STAT, 
Abbott Diagnostics, IL, USA) as previously described. This assay 
has an LoD of 1.2 ng/L and based on our previous work an LoQ 
of 1.5 ng/L (at 20% CV).6
Myocardial biopsy and histological analysis
Tru-cut myocardial biopsies were obtained from 10 patients 
in the mechanism cohort who underwent AVR and also had 
cMyC measured. For autophagy and oncosis assessment, forma-
lin-fixed, paraffin-embedded 4 µm thick tissue sections were cut 
and dehydrated. Further details of the histological analysis are 
provided in the online supplementary material.
Statistical analysis
Statistical analysis was performed using the statistical software 
R V.3.3.2 (http://www. r- project. org). Continuous variables are 
presented as mean (SD) or median (IQR) for non-parametric 
data. We used analysis of variance to compare continuous para-
metric data and the Kruskal-Wallis test for non-parametric data 
across tertiles of cMyC. Categorical variables are presented as 
absolute numbers (percentage) and were compared using χ2 test. 
Due to the positive skewing in the sample, cMyC concentrations 
were log transformed prior to inclusion in modelling. Multivar-
iate linear regression modelling was used to assess the change in 
markers of aortic stenosis severity with serum cMyC concentra-
tion. Receiver operating characteristic (ROC) curve analysis and 
multivariate logistic regression modelling were used to assess the 
relationship between cMyC concentrations and LGE. Survival 
analysis was performed with a Kaplan-Meier analysis using time 
to any cause of death, with significance calculated by log-rank 
test. This relationship was also assessed using Cox proportional 
hazard modelling. AVR was included as a time-varying covariate 
as survival could be expected to improve in those who received 
surgery during the follow-up period. A value of P<0.05 was 
considered statistically significant.
ReSulTS
The mechanism cohort consisted of 161 individuals with 
aortic stenosis (mean age 69 years, AVmax 3.8±0.9 m/s, 70% 
male) and 46 healthy control participants (mean age 58 years, 
AVmax 1.4±0.2 m/s, 63% male). The outcome cohort consisted of 
104 patients (mean age 68 years, AVmax 3.4±0.7 m/s, 68% male) 
with a median follow-up period of just more than 11 years (4067 
(3882–4161) days).
Baseline characteristics by tertile of cMyC are presented in 
tables 1 and 2 for the mechanism and outcome cohorts. cMyC 
was measurable above the LLoQ (1.2 ng/L) in all but one subject, 
giving an overall detection rate of 99.7%, including all healthy 
controls (online supplementary figure S1). Similar to observa-
tions with cardiac troponin, cMyC concentrations were posi-
tively skewed across all cohorts (online supplementary figure S2) 
and weakly correlated with renal function (online supplemen-
tary figure S3). The median cMyC concentration was similar 
among patients with aortic stenosis in the mechanism (20.5 
(13.7–33.2) ng/L) and outcome (18.2 (12.2–30.1) ng/L) cohorts 
(P=0.21), with both being higher than in controls (9.5 (7.6–
15.1) ng/L, P<0.001 for both). Samples were tested in duplicate, 
with a CV between repeated measurements of 5.9%±5.1% in 
the mechanism cohort, 6.1%±4.9% across the outcome cohort 
and 8.5%±4.5% in controls.
Cardiac troponin concentrations were above the LLoQ in 
92.3% of subjects, but in only 65.2% of healthy controls. A 
strong correlation was observed between cMyC and cardiac 
troponin across all samples tested (r=0.74, 95% CI 0.69 to 0.79, 
P<0.0001, online supplementary figure S1).
cMyC and mechanistic imaging markers
In adjusted multiple regression analyses, cMyC concentra-
tion was associated with indexed LV mass in those with aortic 
stenosis who underwent CMR imaging (β=11.0 g/m2 per 
log unit increase in cMyC after adjustment for age, sex, renal 
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function, AVmax, cardiac troponin and comorbidity; 95% CI 4.7 
to 17.3, P<0.001, figure 1A). This relationship was numerically 
positive, but did not approach statistical significance among 
healthy controls (β=2.7 g/m2, 95% CI −4.8 to 10.1, P=0.47, 
online supplementary figure S4). Similarly, fibrosis volume was 
related to cMyC in those with aortic stenosis (adjusted β=8.0 g 
per log unit increase in cMyC; 95% CI 3.5 to 12.6, P<0.001, 
figure 1B) but not in controls (β=1.8 g, 95% CI −1.6 to 5.2, 
P=0.28, online supplementary figure S4). ECV as a marker of 
diffuse myocardial fibrosis was associated with cMyC in patients 
with aortic stenosis (adjusted β=1.3%, 95% CI 0.3% to 2.3%, 
P=0.01), but not in healthy controls (adjusted β=0.5%, 95% CI 
−0.5% to 1.5%, P=0.32). Detailed modelling is shown in online 
supplementary tables S1–S3. cMyC concentrations were related 
to severity of aortic stenosis across the range of AVmax measures 
in the mechanism cohort (adjusted β=0.80 m/s, 95% CI 0.50 
to 1.10, P<0.001, figure 1C), although this was not observed 
in the narrower range included in the outcome cohort (online 
supplementary figure S4). An association was further noted 
between cMyC and diastolic function, measured by echocardi-
ography E/e′ in the mechanism cohort (adjusted β=3.76, 95% CI 
1.21 to 6.32, P=0.004, figure 1D). There was no relationship 
between cMyC and objective measures of coronary disease by 
CT calcium scoring (adjusted β=0.03, 95% CI −0.17 to 0.23, 
P=0.76, online supplementary figure S4).
Table 1 Baseline characteristics of the mechanism cohort by tertile of cMyC and controls
All
(n=161)
Tertile 1
3–16 ng/l
(n=54)
Tertile 2
17–28 ng/l
(n=55)
Tertile 3
29–171 ng/l
(n=52) P value
Controls
(n=46)
Age (years) 68.5 (11.4) 64.3 (13.0) 69.4 (9.3) 71.8 (10.5) 0.002 57.9 (20.5)
Sex (male), n (%) 112 (69.6) 29 (53.7) 42 (76.4) 41 (78.8) 0.008 29 (63.0)
BMI (kg/m2) 28.9 (4.8) 29.1 (5.2) 28.7 (4.0) 29.0 (5.1) 0.88 26.8 (3.8)
BSA (m2) 1.9 (0.2) 1.9 (0.2) 1.9 (0.2) 1.9 (0.2) 0.71 1.9 (0.2)
Comorbidity
  Diabetes mellitus, 
n (%)
24 (14.9) 9 (16.7) 6 (10.9) 9 (17.3) 0.59 0 (0.0)
  Hypertension, n (%) 109 (67.7) 30 (55.6) 42 (76.4) 37 (71.2) 0.06 12 (26.1)
  Hyperlipidaemia, n (%) 72 (44.7) 20 (37.0) 22 (40.0) 30 (57.7) 0.07 8 (17.4)
  IHD, n (%) 61 (37.9) 12 (22.2) 23 (41.8) 26 (50.0) 0.01 2 (4.3)
  Previous PCI, n (%) 25 (15.5) 6 (11.1) 8 (14.5) 11 (21.2) 0.35 2 (4.3)
  Previous CABG, n (%) 7 (4.4) 2 (3.7) 1 (1.9) 4 (7.7) 0.33 0 (0.0)
Medications
  Antiplatelet, n (%) 79 (49.1) 17 (31.5) 29 (52.7) 33 (63.5) 0.004 7 (15.2)
  ACE-I/ARB, n (%) 67 (41.6) 16 (29.6) 28 (50.9) 23 (44.2) 0.07 9 (19.6)
  Beta blocker, n (%) 55 (34.2) 16 (29.6) 17 (30.9) 22 (42.3) 0.32 5 (10.9)
  Diuretic, n (%) 52 (32.3) 16 (29.6) 21 (38.2) 15 (28.8) 0.51 4 (8.7)
Blood tests
  Creatinine (μmol/L) 79.1 (17.1) 73.5 (11.1) 78.6 (15.5) 85.2 (21.5) 0.002 72.5 (15.3)
  eGFR (mL/min/1.73 m2) 86.3 (18.5) 89.0 (15.9) 88.0 (18.8) 81.7 (20.1) 0.09 97.7 (19.8)
  Troponin I (ng/L) 6.6 (3.8–12.3) 3.3 (2.3–4.5) 6.7 (4.8–9.5) 15.5 (10–30.2) <0.001 2.7 (1.1–5.4)
Echo parameters
  AVmax (m/s) 3.8 (0.9) 3.4 (0.8) 3.9 (0.8) 4.3 (0.9) <0.001 1.4 (0.2)
  AV area (cm2) 1.0 (0.4) 1.1 (0.4) 0.9 (0.3) 0.9 (0.4) 0.006 2.4 (0.6)
  AV MPG (mm Hg) 34.4 (18.6) 25.9 (13.5) 34.5 (16.6) 43.2 (21.3) <0.001 4.2 (1.4)
  Indexed LV mass (g/m2) 122.7 (32.0) 102.3 (22.8) 127.6 (27.3) 139.4 (33.7) <0.001 93.2 (24.4)
  E/e′ 14.6 (7.6) 12.4 (4.8) 13.1 (5.0) 18.3 (10.4) <0.001 8.6 (2.5)
MRI parameters
  Indexed LV mass (g/m2) 88.8 (21.5) 74.2 (15.2) 90.1 (16.6) 102.5 (22.1) <0.001 65.8 (13.7)
  Ejection fraction (%) 66.8 (7.3) 67.5 (5.6) 65.8 (8.3) 67.2 (7.8) 0.44 64.4 (4.4)
  Indexed SV (mL/m2) 47.6 (10.2) 44.3 (8.4) 47.1 (9.6) 51.4 (11.2) 0.001 46.1 (8.2)
  Indexed ESV (mL/m2) 24.2 (9.8) 21.6 (6.6) 25.5 (11.5) 25.6 (10.2) 0.055 26.0 (7.4)
  Indexed EDV (mL/m2) 71.8 (16.9) 65.9 (13.3) 72.6 (17.8) 77.0 (17.8) 0.003 72.1 (14.6)
  ECV (%) 27.8 (2.6) 27.1 (2.2) 27.4 (2.1) 28.9 (3.2) 0.001 26.6 (1.7)
  Fibrosis volume (g) 44.6 (15.3) 36.0 (8.9) 44.2 (11.1) 54.5 (18.5) <0.001 31.0 (7.6)
Outcomes
  AVR, n (%) 41 (25.5) 8 (14.8) 20 (36.4) 13 (25.0) 0.04 0 (0.0)
  Cardiac death, n (%) 1 (0.6) 0 (0.0) 0 (0.0) 1 (1.9) 0.35 0 (0.0)
  All-cause death, n (%) 6 (3.7) 1 (1.9) 1 (1.8) 4 (7.7) 0.19 0 (0.0)
Values are number (%), mean (SD) or median (IQR).  Results in bold are statistically significant.
ACE-I, ACE inhibitor; ARB, angiotensin receptor blocker; AV, aortic valve; AVR, aortic valve replacement.; BMI, body mass index; BSA, body surface area; CABG, coronary artery 
bypass grafting; cMyC, cardiac myosin-binding protein C; ECV, extracellular volume fraction; EDV, end-diastolic volume; eGFR, estimated glomerular filtration rate; ESV, end-
systolic volume; IHD, ischaemic heart disease; PCI, percutaneous coronary intervention; LV, left ventricle; MPG, mean pressure gradient; SV, stroke volume.
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LGE was present in 57 (35.4%) of patients with aortic 
stenosis in the mechanism cohort. cMyC concentrations were 
almost double in those with evidence of LGE compared with 
those without (32.3 (21.3–56.3) ng/L vs 17.2 (11.5–24.2) ng/L, 
P<0.001). By ROC analysis, cMyC improved discrimination for 
LGE beyond age and gender (area under the curve (AUC) 0.77, 
95% CI 0.70 to 0.85, figure 2A). A sensitivity analysis restricted 
to those with mid-wall fibrosis only (77% of those with any LGE) 
demonstrated similar discrimination (AUC 0.77, 95% CI 0.70 
to 0.84). Using logistic regression modelling adjusted for age 
and sex, the predicted probability of LGE was seen to progres-
sively increase with cMyC concentration (figure 2B). Univar-
iate correlations between cMyC and baseline variables used for 
covariate adjustment in the mechanism cohort are presented in 
online supplementary table S4.
cMyC and myocyte death
Clear differences were observed in staining patterns for oncosis 
and autophagy between subjects with low and high cMyC concen-
trations (figure 3). Exploratory analysis suggested a relationship 
between cMyC and the rate of myocyte death (expressed as the 
sum of apoptosis, oncosis and autophagy counts) in 10 subjects 
with myocardial biopsy tissue taken at the time of AVR (r=0.67, 
95% CI 0.08 to 0.92, P=0.03, online supplementary figure S5). 
cMyC and long-term outcomes
Subjects in the outcome cohort were stratified by tertile of cMyC 
(table 2). As with CMR in the mechanism cohort, indexed LV 
mass by echocardiography increased across tertiles of cMyC 
(170.0±56.8 g in lowest tertile vs 208.7±52.0 g in highest tertile, 
P=0.004). There were no consistent differences in cardiac risk 
factors across the tertiles. During the follow-up period, 36 
(34.6%) subjects died, of which 16 (15.4%) were adjudicated as 
cardiac deaths. Forty-eight patients (46.2%) within the cohort 
underwent surgical AVR, with no cases of transcatheter aortic 
valve implantation undertaken. There was a trend towards 
poorer survival over the period of follow-up with increasing 
tertile of cMyC (figure 4, log-rank test for difference P=0.07).
In Cox proportional hazards analysis, cMyC concentration 
was associated with an increased risk of all-cause mortality over 
the follow-up period after inclusion of AVR as a time-varying 
covariate (HR 1.49 per log unit increase of cMyC, 95% CI 1.11 
to 2.01, P=0.009). However, following adjustment for age, sex, 
AVmax or CT coronary calcium scores, statistical significance was 
lost. Age was significantly associated with cMyC in all models 
(online supplementary table S5).
Table 2 Baseline characteristics of the outcome cohort by tertile of cMyC
All patients
(n=104)
Tertile 1
5–14 ng/l
(n=35)
Tertile 2
15–26 ng/l
(n=35)
Tertile 3
27–132 ng/l
(n=34) P value
Age (years) 68.2 (9.8) 64.4 (10.5) 70.1 (9.0) 70.0 (9.1) 0.02
Sex (male), n (%) 71 (68.3) 21 (60.0) 19 (54.3) 31 (91.2) 0.002
BMI (kg/m2) 27.9 (4.5) 27.6 (4.1) 28.1 (4.9) 27.8 (4.7) 0.91
BSA (m2) 1.9 (0.2) 1.9 (0.2) 1.9 (0.2) 2.0 (0.2) 0.19
Comorbidity
  Diabetes mellitus, n (%) 2 (1.9) 1 (2.9) 0 (0.0) 1 (2.9) 0.60
  Hypertension, n (%) 57 (54.8) 16 (45.7) 24 (68.6) 17 (50.0) 0.13
  Hyperlipidaemia, n (%) 7 (6.7) 0 (0.0) 5 (14.3) 2 (5.9) 0.06
  IHD, n (%) 17 (16.3) 2 (5.7) 10 (28.6) 5 (14.7) 0.03
Medications
  Aspirin, n (%) 42 (40.4) 13 (37.1) 16 (45.7) 13 (38.2) 0.74
  Anticoagulant, n (%) 10 (9.6) 1 (2.9) 4 (11.4) 5 (14.7) 0.23
  ACE-I/ARB, n (%) 20 (19.2) 5 (14.3) 7 (20) 8 (23.5) 0.63
  Beta blocker, n (%) 23 (22.1) 8 (22.9) 11 (31.4) 4 (11.8) 0.14
Blood tests
  Creatinine (μmol/L) 91.3 (21.3) 85.3 (18.1) 89.3 (17.9) 100.1 (25.6) 0.01
  eGFR (mL/min/1.73 m2) 73.5 (17.4) 77.2 (13.9) 71.7 (16.4) 71.6 (21.3) 0.31
  Troponin I (ng/L) 7.2 (5.4–12.6) 4.9 (3.9–6.0) 8.3 (6.7–10.6) 14.3 (12.1–17.9) <0.001
Echo parameters
  AVmax (m/s) 3.4 (0.7) 3.4 (0.7) 3.4 (0.8) 3.5 (0.6) 0.90
  AV area (cm2) 1.0 (0.4) 1.0 (0.4) 1.0 (0.4) 1.0 (0.4) 0.89
  AV MPG (mm Hg) 48.8 (19.2) 47.6 (18.7) 49.7 (21.8) 49.2 (17.1) 0.89
  Indexed LV mass (g/m2) 184.4 (52.2) 170.0 (56.8) 175.7 (38.8) 208.7 (52.0) 0.004
  Ejection fraction (%) 66 (31) 69 (22) 66 (25) 61 (44) 0.64
CT coronary calcium score 382.6 (611.1) 370.3 (608.3) 491.0 (783.2) 283.6 (360.2) 0.37
Outcomes
  AVR, n (%) 48 (46.2) 19 (54.3) 15 (42.9) 14 (41.2) 0.49
  Cardiac death, n (%) 16 (15.4) 4 (11.4) 7 (20.0) 5 (14.7) 0.61
  All-cause death, n (%) 36 (34.6) 7 (20.0) 14 (40.0) 15 (44.1) 0.08
Values are number (%), mean (SD) or median (IQR). Results in bold are statistically significant.
ACE-I, ACE inhibitor; ARB, angiotensin receptor blocker; AV, aortic valve; AVR, aortic valve replacement; BMI, body mass index; BSA, body surface area; cMyC, cardiac myosin-
binding protein C; eGFR, estimated glomerular filtration rate; IHD, ischaemic heart disease; LV, left ventricle; MPG, mean pressure gradient.
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dISCuSSIOn
In a comprehensive series of clinical assessments, we report 
the relationship between serum cMyC concentration, a novel 
marker of myocardial injury, and cardiac structure and outcomes 
in patients with aortic stenosis. We have made several important 
observations. First, serum cMyC concentrations can be reliably 
quantified in the vast majority of patients with aortic stenosis. 
Second, cMyC strongly associates with markers of both diffuse 
Figure 1 Relationships between cMyC and markers of disease severity in the mechanism cohort. β values (95% CI) represent change in the 
progression variable for each log unit change in cMyC concentration after adjustment in multivariate modelling. Markers of disease severity are: (A) 
indexed LV mass (g/m2) determined by MRI; (B) fibrosis volume (g) by MRI; (C) AVmax (m/s) determined by echocardiography; (D) diastolic function 
from echocardiographic measures of E/e′ ratio. *Adjusted for age, sex, glomerular filtration rate, AVmax, cardiac troponin, history of ischaemic heart 
disease, diabetes and hypertension. +As above plus body surface area. ‡As above excluding AVmax. AV, aortic valve; cMyC, cardiac myosin-binding 
protein C; LV, left ventricle.
Figure 2 cMyC and late gadolinium enhancement. (A) Receiver operating characteristic (ROC) curve analysis for outcome of LGE. Addition of 
cMyC improves the prediction of age and gender for LGE, P=0.002 (DeLong’s method with bootstrapping). (B) Logistic regression modelling for 
the predicted probability of LGE with serum cMyC concentration (adjusted for age and sex). Shaded area represents 95% CI. AUC, area under the 
curve; cMyC, cardiac myosin-binding protein C; LGE, late gadolinium enhancement. 
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interstitial and focal replacement fibrosis as well as indexed 
LV mass, a marker of the hypertrophic response to aortic 
stenosis. These observations were independent of the severity of 
valve stenosis and cMyC concentrations were unrelated to coro-
nary artery disease. Third, cMyC concentrations are strongly 
correlated with cardiac troponin, and in histological analyses 
are associated with myocyte cell death, suggesting that sarco-
meric protein release is a direct consequence of the maladaptive 
myocardial response to aortic stenosis. We believe these novel 
observations demonstrate the utility and validity of cMyC as a 
marker of sustained chronic myocardial injury.
Assay performance
The release profile of cMyC has been previously studied after 
acute injury in myocardial infarction, alcohol ablation for hyper-
trophic cardiomyopathy and coronary artery bypass grafting.7 16 
These models have shown cMyC to be more abundant, to be 
released earlier following injury and to decline more rapidly when 
compared with cardiac troponin. These observations suggest 
that cMyC has enhanced potential for dynamic monitoring of 
myocardial injury and disease. However, previous generations 
of the cMyC assay had limited sensitivity at the low levels that 
would be expected in the presence of chronic myocardial injury 
such as in aortic stenosis. For example, cMyC was only detect-
able in 2 out of 20 patients with hypertrophic cardiomyopathy.24 
Here we report cMyC measurements from a high-sensitivity 
assay using magnetic nanoparticle and single molecule counting 
technology, and demonstrate near universal quantification in 
patients with aortic stenosis and healthy controls.
cMyC as a biomarker of disease
Our observations suggest cMyC is a sensitive marker of the 
hypertrophic and subsequent fibrotic myocardial response to 
Figure 3 Patterns of myocyte death in patients with aortic 
stenosis. Images showing differing patterns of oncosis and autophagy 
visualised using a 3,3′-diaminobenzidine-based detection kit in 
individuals with aortic stenosis. (A) Oncosis and (B) autophagy in a 
patient with a low (9.4 ng/L) cMyC concentration. (C) Oncosis and (D) 
autophagy in a patient with a high (87.2 ng/L) cMyC concentration. 
There is a marked difference in staining intensity by cMyC concentration 
for both oncosis and autophagy. cMyC, cardiac myosin-binding   
protein C.
Figure 4 Survival by tertiles of cMyC in the outcome cohort. cMyC, cardiac myosin-binding protein C.
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aortic stenosis. ECV fraction on CMR T1 mapping is a marker 
of diffuse interstitial fibrosis, which may precede the focal 
mid-wall replacement fibrosis detected by LGE.19 20 Histological 
studies have suggested that myocyte death drives this transition.5 
Our exploratory analysis in myocardial biopsy tissue relates 
combined measures of autophagy, oncosis and apoptosis to 
serum cMyC concentrations, providing histological correlation 
of biomarker release as a result of myocyte death. This combi-
nation of autophagy and oncosis in failing myocardial tissue has 
been independently associated with mortality in larger studies.25
Our observations are consistent with our previous findings 
using a high-sensitivity cardiac troponin I assay. Using two inde-
pendent sarcomeric proteins, we have now demonstrated that 
serum markers of myocardial injury mirror important patholog-
ical changes in the myocardium in response to aortic stenosis.6 26 27 
Similar to cardiac troponin, although cMyC was related to AVmax 
by echocardiography in the mechanism cohort, its association 
with markers of hypertrophy, fibrosis and diastolic function was 
independent of the severity of aortic stenosis. This suggests that 
these novel markers of the myocardial response to stenosis will 
add to conventional clinical assessment in aortic stenosis. While 
CMR imaging provides important detail on the extent of the 
progression to fibrosis and heart failure, it is a resource-inten-
sive investigation.2 28 As such, there is great potential for simple 
blood measures of myocardial injury to improve decision-making 
in aortic stenosis, to better target detailed imaging or even help 
determine the timing of surgery. Current guidelines advocate 
AVR in the presence of LV impairment or symptoms, but these 
are challenging to define objectively and may signify that irre-
versible myocardial fibrosis has already developed. A precise and 
early marker of myocardial injury such as cMyC may have great 
clinical utility in patients with aortic stenosis.
We demonstrate an increased mortality risk with rising cMyC 
concentrations, but this association was not independent of 
other variables. Our outcome cohort benefits from extensive 
follow-up over 11 years after sampling, but the cohort size was 
restricted by limited remaining stored samples. This analysis 
is likely to be underpowered and further work is required in 
larger studies to clarify whether cMyC will provide additional 
prognostic information in the assessment of patients with aortic 
stenosis.
limitations
We acknowledge some limitations with the current study in addi-
tion to sample size. There is only limited overlap for compar-
ison of imaging endpoints between our two cohorts, although 
the magnitude of associations between cMyC and LV mass 
are similar. The clinical utility of biomarkers such as cMyC is 
more likely to be of interest in severe cases of aortic stenosis 
approaching the need for valve replacement, where myocar-
dial injury becomes more pronounced. Our mechanism and 
outcome cohorts contained only 84 and 52 patients with severe 
aortic stenosis, respectively. While this represents half of our 
study population, further evaluation in a larger population with 
severe disease would be informative. The histological analysis 
presented is exploratory and the Tru-cut technique used may 
provide limited volumes of myocardium compared with novel 
scalpel methods.29
Our findings add to our previous observations with cardiac 
troponin.6 26 27 Compared with those assays, the latest genera-
tion cMyC assay is still in the early stages of development, with 
no definitive healthy population studies to derive a normal refer-
ence range. However, our study suggests that the biomarker will 
be measurable in virtually all individuals and is likely to meet the 
criteria for a high-sensitivity assay.30 Larger cohort studies are 
necessary to assess the relationship and potential differences in 
cMyC and cardiac troponin release, and to determine whether 
the association of cMyC and long-term outcomes is independent 
of other patient factors and cardiac biomarkers. Further valida-
tion with prospective serial sampling of cMyC in patients with 
aortic stenosis prior to clinical decompensation is now required.
COnCluSIOnS
Serum cMyC concentration is associated with myocardial hyper-
trophy, fibrosis and an increased risk of mortality in aortic 
stenosis. The quantification of serum sarcomeric protein concen-
trations provides objective measures of disease severity and their 
clinical utility to monitor the progression of aortic stenosis 
merits further study.
Key messages
What is already known on this subject?
The progression of aortic stenosis is unpredictable and 
irreversible myocardial fibrosis may develop before symptoms 
are apparent. Cardiac troponin I as a biomarker of myocardial 
injury is associated with advanced hypertrophy, replacement 
fibrosis and poor long-term outcomes in patients with aortic 
stenosis.
What might this study add?
Cardiac myosin-binding protein C (cMyC) is a cardiac sarcomeric 
protein and novel highly sensitive biomarker of acute myocardial 
injury. In two cohorts of patients with aortic stenosis, increasing 
concentrations of cMyC were associated with greater myocardial 
hypertrophy, fibrosis and death, even after adjustment for the 
severity of aortic stenosis and cardiac troponin concentrations. 
This is the first study to measure cMyC using a high-precision 
assay in patients with aortic stenosis.
how might this impact on clinical practice?
Objective blood biomarkers are not currently included in clinical 
guidelines for the management of aortic stenosis. This study adds 
to evidence that quantification of serum sarcomeric proteins 
has major potential to objectively track disease progression 
in this condition. Further validation with prospective serial 
sampling of cMyC in patients with aortic stenosis prior to clinical 
decompensation is now required.
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